Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

Opinion
Video

Panelists discuss how anti-VEGF therapies have dramatically improved visual outcomes in patients with age-related macular degeneration and diabetic macular edema over the past decade. Key challenges persist, including treatment burden, adherence, and identifying optimal dosing regimens for individual patients.

Video content above is prompted by the following:

  • Anti-VEGF treatments have been available for age-related macular degeneration and diabetic macular edema for over a decade. Can you discuss how they have impacted patient outcomes and what barriers remain to achieving optimal results?

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
Related Content
A scientist in a lab looks into a microscope, which is placed on a desk. His face is not fully visible but he wears a lab coat and sits in front of a computer. Concept image for cell therapy, stem cell research, phase 1 clinical trial, and geographic atrophy associated with age-related macular degeneration. Image credit: ©CoetzeeRising/peopleimages.com – stock.adobe.com

Eyestem Research announces positive results from phase 1 geographic atrophy trial

Martin David Harp
April 14th 2025
Article

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A photo of the United States Food and Drug Administration FDA headquarters. Concept image for FDA ophthalmic presbyopia treatment application submission. Image credit: ©Tada Images – stock.adobe.com

Tenpoint Therapeutics submits US FDA New Drug Application for presbyopia treatment BRIMOCHOL PF

Jordana Joy
April 8th 2025
Article

Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A close-up of a doctor's face. The doctor wears PPE including a mask and safety goggles. Oncology and ophthalmology concept image. Image credit: ©H_Ko – stock.adobe.com

New study investigates ocular involvement in multiple myeloma

Lynda Charters
April 1st 2025
Article

Hematologists and ophthalmologists could work together for earlier diagnoses, research findings indicate

An elderly man and his caregiver discuss their budget and financial well-being. Concept image for caretaker, caregiver, aging, age-related macular degeneration. Image credit: ©Andrii Lysenko – stock.adobe.com

International study illuminates economic burden of late-stage age-related macular degeneration

Lynda Charters
March 31st 2025
Article

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

© 2025 MJH Life Sciences

All rights reserved.